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Sepsis is one of the leading causes of death in the ICU.
The pathogenesis of sepsis remains incompletely under-
stood, thereby impeding the development of therapeu-
tics, diagnostics and biomarkers to predict outcomes
[1]. Our previous studies have proved that miR-122,
miR-193b*, miR-483-5p and miR-574-5p were all dif-
ferentially expressed between sepsis survivors and
non-survivors, differentiated by 28-day mortality [2,3].
However, whether these biomarkers related to patients
with both sepsis and acute respiratory distress syn-
drome (ARDS) remains unclear. Here we evaluate the
levels of these four microRNAs (miRNAs) along with
C-reactive protein (CRP), procalcitonin (PCT), Sequen-
tial Organ Failure Assessment (SOFA) score, and Acute
Physiology and Chronic Health Evaluation (APACHE)
II score to determine the ideal biomarkers for sepsis
patients.
Serum samples were collected from 232 sepsis patients
who were admitted to ICUs of the Chinese PLA General
Hospital. All the patients met the definition of sepsis de-
veloped in 2003 [4]. Inclusion and exclusion criteria are
described in Table 1. Another 24 normal individuals
were also included in this study. Serum levels of miRNAs,
CRP and PCT were analyzed using methods as described
in detail previously [3]. This study was approved by the
ethics committee of the Chinese PLA General Hospital.
Appropriate informed consent was obtained from each
patient and normal individual.
The clinical data of these 232 patients are shown in
Table 2. After comparison of the levels of the four miRNAs
in three pairs of groups (normal individuals and sepsis
patients, survivors and non-survivors, sepsis without
ARDS and sepsis plus ARDS), only the cycle threshold of
mir-122 was differentially expressed in all three (P<0. 01 )
(Figure 1). Univariable and multivariable regression ana-
lyses were then used to evaluate the association between
miR-122 and 28-day mortality in different ICUs. After ad-
justment using clinical data and additional parameters
(SOFA score, APACHE II score and ARDS), the odds ratio
of miR-122 association with 28-day mortality was around
0.376 to 0.868 (P<0.05) in the different ICUs. The area
under the curve for the predictive value of miR-122 was
around 0.706 to 0.770 (P<0.01) with high sensitivity and
specificity (Table 3). As a result, only miR-122 can be used
as a biomarker with regards to patients with both sepsis
and ARDS. miR-122 is a liver-specific miRNA and levels
of it in serum were correlated with drug-induced liver in-
jury [5]. We reported that miR-122 correlated with coagu-
lation disorders in sepsis patients and serum levels of
miR-122 correlated with serum antithrombin III levels [6].
Our study reveals a potential novel target to develop a bio-
marker for sepsis prognosis and therapeutic strategies.
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Inclusion criteria Exclusion criteria
1) Sepsis patients all met the definitions of the 2001 SCCM/ESICM/
ACCP/ATS/SIS International Sepsis Definitions Conference [4]
1) Patients who were younger than 18 years old
2) Patients who were immunosuppressed
3) Patients who did not receive adequate treatment
4) Patients who did not give their written informed consent
2) All patients received standard protocols of clinical care
Table 2 Clinical characteristics of the 232 sepsis patients
Category Variables Sepsis (n=232)
Demographic parameters Gender (male/female) 169/63
Age in years (median (range)) 59 (19, 91)
Clinical parameters ICU type
Medical 232 (100%)
Cardiac 79 (34.05%)
Surgical 95 (40.95%)
Trauma 25 (10.77%)
Cancer 24 (10.34%)
Other 15 (6.46%)
APACHE II score 18 (1, 39)
SOFA score 7 (0, 19)
Acute kidney injury 61 (26.29%)
Mechanical ventilation 171 (73.71%)
Heat failure 121 (52.15%)
Liver failure 103 (44.39%)
ARDS 60 (28.17%)
a
28-day mortality 45.69%
Biomarkers miR-122 17.75±3.40 cycles
miR-193b* 17.73±4.81 cycles
miR-574-5p 21.19±3.64 cycles
miR-483-5p 18.99±4.24 cycles
CRP (mg/dl) 8.9 (0.1, 35)
PCT (ng/ml) 4.63 (0.05,119.44)
aARDS data of 19 patients were missing. APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; CRP, C-reactive
protein; PCT, procalcitonin; SOFA, Sequential Organ Failure Assessment. APACHE II score, SOFA score, CRP and PCT are all given as median (range).
*ARDS data of 19 patients were missing.
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All patients (n =232) RICU (n= 67) SICU (n =121) EICU (n= 44)
Odds ratios of miR-122 (95% CI)
Unadjusted
a 0.775 (0.703, 0.853) 0.776 (0.664, 0.908) 0.77 (0.662, 0.894) 0.764 (0.610, 0.956)
P<0.001 P =0.001 P=0.001 P=0.019
Adjusted
b 0.789 (0.713, 0.872) 0.777 (0.663, 0.911) 0.763 (0.655, 0.888) 0.650 (0.474, 0.891)
P<0.001 P =0.002 P<0.001 P=0.007
Adjusted
b + 0.772 (0.690, 0.863) 0.781(0.665, 0.918) 0.791(0.677,0.925) 0.631 (0.448, 0.890)
SOFA score P<0.001 P =0.003 P=0.003 P=0.009
Adjusted
b + 0.815 (0.734, 0.905) 0.709 (0.578, 0.870) 0.753 (0.639, 0.887) 0.622 (0.431, 0.897)
APACHE II score P<0.001 P =0.001 P=0.001 P=0.011
Adjusted
b + 0.812 (0.724, 0.911) 0.868 (0.647, 0.967) 0.721 (0.599, 0.867) 0.376 (0.133, 0.865)
ARDS P<0.001 P =0.023 P=0.001 P=0.034
The predictive value of miR-122
AUC (95% CI) 0.732 (0.665, 0.799) 0.763 (0.65,0.877) 0.706 (0.611,0.802) 0.770 (0.574, 0.966)
P-value < 0.001 < 0.001 < 0.001 0.009
Sensitivity 79.5% 75.9% 79.4% 80%
Specificity 63.5% 70.3% 60.7% 81.8%
aUnadjusted by any value.
bAdjusted by age and gender. APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; AUC, are
under the curve; EICU, Emergency Intensive Care Unit; RICU, Respiratory Intensive Care Unit; SICU, Surgery’s Intensive Care Unit; SOFA, Sequential Organ Failure Assessment.
Figure 1 Cycle thresholds of the four microRNAs (miRNAs) in the three pairs of groups. ARDS, acute respiratory distress syndrome.
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